Immix Biopharma (IMMX)
(Delayed Data from NSDQ)
$2.05 USD
+0.01 (0.49%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $2.03 -0.02 (-0.98%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Immix Biopharma, Inc. [IMMX]
Reports for Purchase
Showing records 1 - 20 ( 51 total )
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
US CAR-T trial commences patient dosing
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Reaffirmed long-term focus on outpatient CAR-T
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Marching towards US clinical trials for NXC-201
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
2023 recap with a preview of active year ahead
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Updates galore: NXC-201 ODD (EU) and raise
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Increased legroom following common-only raise
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging stream of ALA data newsflow
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
100% ORR Continues for NXC-201 in ALA, 10 Patients Evaluated Thus Far
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
KOL Call Underscores Unmet ALA Need NXC-201''s Potential & Opportunity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
CAR-T trial moves to US with outpatient potential
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
A quarter of progress for both lead assets
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
A step toward delivering a practical CAR-T option
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
New NXC-201 ALA Data - 100% ORR 67% CR In Heavily Refractory Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
Updated NXC-201 Results Show Continued Potency in Rel/Ref MM Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Immix Biopharma, Inc.
Industry: Medical - Biomedical and Genetics
NXC-201 gains orphan drug designation in ALA
Provider: Edison Investment Research Limited
Analyst: ROMANOFF S